Eli Lilly and Company has launched a new single-dose vial option for Zepbound, its hemophilia B treatment, providing flexible and affordable access for cash-paying patients who may not have insurance coverage or prefer not to use insurance for the medication.
Indianapolis, Indiana – Eli Lilly and Company, a global leader in the pharmaceutical industry, has announced the introduction of a single-dose vial of Zepbound, its recombinant coagulation factor IX injection indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children with hemophilia B. This new packaging option provides cash-paying patients with greater flexibility and affordability when accessing this critical treatment.
The monthly price of the 2.5 mg Zepbound single-dose vial is $399, and the 5 mg dose is $549. These prices are aligned with the savings program Lilly already offers for Zepbound, which provides a 20% discount to cash-paying patients.
Lilly Unveils Zepbound Single-Dose Vial, Tailored for Cash-Paying Patients
"We understand that patients with hemophilia B face unique challenges, including managing the cost of their treatment," said Patrik Jonsson, Vice President of Lilly Bio-Medicines. "The introduction of the Zepbound single-dose vial is a testament to our commitment to making our therapies more accessible and affordable for all patients."
The single-dose vial offers several advantages for cash-paying patients:
* **Flexibility:** The single-dose vial provides greater flexibility for patients who may not be able to afford the full cost of multi-dose vials.
* **Affordability:** The single-dose vial is a more affordable option for patients who are not eligible for insurance coverage or who prefer to pay out-of-pocket.
* **Simplicity:** The single-dose vial eliminates the need for mixing and reconstitution, making it easier for patients to administer their treatment themselves.
"The Zepbound single-dose vial is a welcome addition to the treatment options available to patients with hemophilia B," said Dr. Barbara Konkle, a hematologist at Children's Hospital of Philadelphia. "This packaging option provides greater flexibility and affordability, empowering patients to make informed decisions about their care."
Lilly's commitment to affordable healthcare extends beyond the introduction of the Zepbound single-dose vial. The company has established several programs to help patients with hemophilia B access financial assistance, including:
* **Lilly Cares Patient Assistance Program:** This program provides free medication to eligible patients who meet certain financial criteria.
* **Patient Assistance Network Foundation:** Lilly supports this independent foundation, which provides financial assistance to patients with chronic or life-threatening diseases, including hemophilia.
* **Hemophilia Foundation of America:** Lilly collaborates with this organization to provide financial and educational support to patients with hemophilia and their families.
"We are committed to ensuring that every patient with hemophilia B has access to the treatment they need," said Jonsson. "We believe that the introduction of the Zepbound single-dose vial, coupled with our comprehensive financial assistance programs, empowers patients and improves their quality of life."
